Your browser doesn't support javascript.
loading
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease.
Cazanave, Sophie; Podtelezhnikov, Alexei; Jensen, Kristian; Seneshaw, Mulugeta; Kumar, Divya P; Min, Hae-Ki; Santhekadur, Prasanna K; Banini, Bubu; Mauro, Adolfo Gabriele; M Oseini, Abdul; Vincent, Robert; Tanis, Keith Q; Webber, Andrea L; Wang, Liangsu; Bedossa, Pierre; Mirshahi, Faridoddin; Sanyal, Arun J.
Afiliación
  • Cazanave S; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. sccncazanave@gmail.com.
  • Podtelezhnikov A; Merck Research Laboratories, Kenilworth, NJ, USA.
  • Jensen K; Merck Research Laboratories, Kenilworth, NJ, USA.
  • Seneshaw M; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Kumar DP; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Min HK; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Santhekadur PK; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Banini B; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Mauro AG; VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
  • M Oseini A; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Vincent R; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Tanis KQ; Merck Research Laboratories, Kenilworth, NJ, USA.
  • Webber AL; Merck Research Laboratories, Kenilworth, NJ, USA.
  • Wang L; Merck Research Laboratories, Kenilworth, NJ, USA.
  • Bedossa P; Department of Pathology, Hospital Beaujon, University Paris-Diderot, Paris, France.
  • Mirshahi F; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Sanyal AJ; Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. arun.sanyal@vcuhealth.org.
Sci Rep ; 7(1): 17193, 2017 12 08.
Article en En | MEDLINE | ID: mdl-29222421
A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of human disease. The hepatic transcriptome of such mice with fatty liver (8 weeks), steatohepatitis with early fibrosis (16-24 weeks) and advanced fibrosis (52 weeks) after initiation of the diet was evaluated and compared to mice on chow diet. Fatty liver development was associated with transcriptional activation of lipogenesis, FXR-RXR, PPAR-α mediated lipid oxidation and oxidative stress pathways. With progression to steatohepatitis, metabolic pathway activation persisted with additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage activation, prothrombin activation and hepatic stellate cell activation. Progression to advanced fibrosis was associated with dampening of metabolic, oxidative stress and cell stress related pathway activation but with further Fc macrophage activation, cell death and turnover and activation of cancer-related networks. The molecular progression of NAFLD involves a metabolic perturbation which triggers subsequent cell stress and inflammation driving cell death and turnover. Over time, inflammation and fibrogenic pathways become dominant while in advanced disease an inflammatory-oncogenic profile dominates.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Perfilación de la Expresión Génica / Enfermedad del Hígado Graso no Alcohólico Límite: Animals Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Progresión de la Enfermedad / Perfilación de la Expresión Génica / Enfermedad del Hígado Graso no Alcohólico Límite: Animals Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos